详情页 - 首都医科大学附属北京同仁医院知识库

当前位置：首页 > 详情页

CAR-T cell therapy: Where are we now, and where are we heading?

5| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ 卓越：高起点新刊 ◇ ESCI ◇ 中华系列

作者：

机构： [1]Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.

出处：

DOI：

ISSN：

关键词： Chimeric antigen receptor T-cell therapy Cytokine release syndrome Efficacy Hematology

摘要：

Chimeric antigen receptor (CAR)-T-cell therapies have exhibited remarkable efficacy in the treatment of hematologic malignancies, with 9 CAR-T-cell products currently available. Furthermore, CAR-T cells have shown promising potential for expanding their therapeutic applications to diverse areas, including solid tumors, myocardial fibrosis, and autoimmune and infectious diseases. Despite these advancements, significant challenges pertaining to treatment-related toxic reactions and relapses persist. Consequently, current research efforts are focused on addressing these issues to enhance the safety and efficacy of CAR-T cells and reduce the relapse rate. This article provides a comprehensive overview of the present state of CAR-T-cell therapies, including their achievements, existing challenges, and potential future developments.Copyright © 2023 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the Chinese Medical Association (CMA) and Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College (IHCAMS).

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

无

最新[2025]版：

大类 | 4 区医学

小类 | 4 区血液学

JCR分区：

出版当年[2021]版：

无

最新[2023]版：

Q3 HEMATOLOGY

影响因子： 1.5 最新[2023版] 1.4 最新五年平均 0 出版当年[2021版] 0 出版当年五年平均 0 出版前一年[2020版] 1 出版后一年[2022版]

第一作者：

第一作者机构： [1]Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Potential targets for diabetic wound healing through chimeric antigen receptor T cell therapy [2]Chimeric antigen receptor T-cell therapy, where are we now and where are we heading for [3]Toxic epidermal necrosis caused by programmed cell death protein 1 inhibitors in a patient receiving chimeric antigen receptor-T cell therapy [4]Mitoxantrone Hydrochloride Liposome Combined with Polatuzumab Vedotin and Dexamethasone (MPD) Is Highly Effective and Well Tolerated As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma [5]The Hematology and Eye Disease [6]体检者的舌色与外周血7项红细胞参数的相关性研究 [7]高压氧应用于肛周坏死性筋膜炎术后的疗效观察(附12例报告) [8]晚期前列腺癌患者间歇性内分泌治疗的疗效观察 [9]西格列汀与二甲双胍联用治疗老年2型糖尿病的疗治效观察 [10]Efficacy and safety of lapatinib in Chinese breast cancer patients: a real-world study